ESR2 and breast carcinoma: It is known, however, that ERβ, unlike ERα, acts as an oncosuppressor, by antagonizing hormone-induced carcinogenesis and inhibiting growth and oncogenic functions of cancer cells in luminal-like breast cancers [13].